Arnold Seto
Interventional Cardiology · Orange, CANPI 1215081807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $167,110 of the $213,719 with a category attached, or 78.2%. Johnson & Johnson accounts for 67.9% of it on its own, with 45 other manufacturers making up the rest. Reporting peaked in 2019 at $61,029 and has fallen 86.5% since, to $8,209 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $595.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$145K
- Terumo Medical Corporation$17K
- Getinge USA Sales, LLC$9K
- Boston Scientific$7K
- GE HealthCare$6K
- Opsens Inc.$6K
- plus $24K from 40 others
Across 24 payments — averaging $6157.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cathworks, Inc.$75K
- Pfizer$44K
- Amgen$15K
- Novartis$8K
- Gentuity, LLC$5K
What the payments were for
- Consulting fees$29,64414%
- Speaking & faculty fees$167,11078%
- Grants$1000%
- Travel & lodging$5,2942%
- Food & beverage$11,5265%
- Education$290%
- Entertainment$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$143,630
- OptoWire$6,148
- OptoMonitor$6,148
- GENERAL VASCULAR ACCESS$6,000
- CARDIOSAVE$5,479
- TR Band$5,239
- Optitorque$4,475
- VISIPAQUE$4,076
- Glidesheath$3,922
- HD-IVUS$3,413
- Vasoview Hemopro 2$3,200
- Heartrail$2,275
- Spectranetics Undiv$1,688
- CARDIOSAVE HYBRID, TYPE B PLUG$1,600
- GLIDESHEATH SLENDER$1,575
- AVEIR$1,064
- MYNX CONTROL$542
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$529
- Aggrastat (tirofiban HCl)$500
- Paradise Ultrasound Renal Denervation System$400
How this compares
$213,719 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 18 | $29,233 |
| Atorvastatin Calcium | 46 | $566 |
| ClopidogrelClopidogrel Bisulfate | 17 | $275 |
| Ezetimibe | 14 | $245 |
| Rosuvastatin Calcium | 22 | $229 |
| Losartan Potassium | 17 | $163 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 12 | $153 |
| Lisinopril | 11 | $39 |
| Amlodipine Besylate | 18 | $25 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $145,067 | $29,23318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Orange
- Brian KolskiOrange$534K
- Jeffrey TylerOrange$411K
- Antonio Halais FrangiehOrange$208K
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.